These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2387525)

  • 21. Pharmacology of bismuth-containing compounds.
    Lambert JR
    Rev Infect Dis; 1991; 13 Suppl 8():S691-5. PubMed ID: 1925310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mucosa protectives: sucralfate and colloidal bismuth subcitrate in peptic ulcer disease.
    Tytgat GN; Nio CY
    Z Gastroenterol; 1987 Aug; 25 Suppl 3():152-61. PubMed ID: 3660894
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of food and antacid on binding of sucralfate to normal and ulcerated gastric and duodenal mucosa in rats.
    Giesing DH; Bighley LD; Iles RL
    J Clin Gastroenterol; 1981; 3(Suppl 2):111-6. PubMed ID: 6895642
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparative dynamic study of the effectiveness of gastric cytoprotection by vitamin A, De-Nol, sucralfate and ulcer healing by pirenzepine in patients with chronic gastric ulcer (a multiclinical and randomized study).
    Patty I; Tárnok F; Simon L; Jávor T; Deák G; Benedek S; Kenéz P; Nagy L; Mózsik G
    Acta Physiol Hung; 1984; 64(3-4):379-84. PubMed ID: 6397969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Administration of sucralfate prolongs survival of animals with experimental peptic ulceration.
    Mall A; Fourie J; McLeod H; Muschol A; Campbell JA; Hickman R
    Am J Med; 1991 Aug; 91(2A):37S-42S. PubMed ID: 1715672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gastrocytoprotection by colloidal bismuth subcitrate (De-Nol) and sucralfate. Role of endogenous prostaglandins.
    Konturek SJ; Radecki T; Piastucki I; Brzozowski T; Drozdowicz D
    Gut; 1987 Feb; 28(2):201-5. PubMed ID: 3470240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro susceptibility of Campylobacter pyloridis to cimetidine, sucralfate, bismuth and sixteen antibiotics.
    Andreasen JJ; Andersen LP
    Acta Pathol Microbiol Immunol Scand B; 1987 Apr; 95(2):147-9. PubMed ID: 3591312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topically active drugs in the treatment of peptic ulcers. Focus on colloidal bismuth subcitrate and sucralfate.
    Bianchi Porro G; Parente F
    J Clin Gastroenterol; 1992 Apr; 14(3):192-8. PubMed ID: 1348753
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Colloidal bismuth subcitrate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease.
    Wagstaff AJ; Benfield P; Monk JP
    Drugs; 1988 Aug; 36(2):132-57. PubMed ID: 3053124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of sucralfate on human gastric bicarbonate secretion and local prostaglandin E2 metabolism.
    Shorrock CJ; Rees WD
    Am J Med; 1989 Jun; 86(6A):2-4. PubMed ID: 2735332
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A potential mechanism of action of colloidal bismuth subcitrate: diffusion barrier to hydrochloric acid.
    Lee SP
    Scand J Gastroenterol Suppl; 1982; 80():17-21. PubMed ID: 6962540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug therapy of peptic ulcer disease.
    Peppercorn MA
    Compr Ther; 1983 Nov; 9(11):47-52. PubMed ID: 6139199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Studies on the gastroprotective and ulcer-healing effects of colloidal bismuth subcitrate.
    Konturek SJ; Radecki T; Piastucki I; Drozdowicz D
    Digestion; 1987; 37 Suppl 2():8-15. PubMed ID: 3622948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Participation of gastroduodenal mucosa prostaglandins in the anti-ulcer effect of venter].
    Vysotskaia RA; Loginov AS; Vasil'ev IuV; Il'chenko AA; Pechkovskaia OI; Bendikov EA
    Biull Eksp Biol Med; 1998 Jul; 126(7):90-3. PubMed ID: 9777208
    [No Abstract]   [Full Text] [Related]  

  • 35. Lipolytic activity of Campylobacter pylori: effect of colloidal bismuth subcitrate (De-Nol).
    Slomiany BL; Kasinathan C; Slomiany A
    Am J Gastroenterol; 1989 Oct; 84(10):1273-7. PubMed ID: 2801678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of gastric mucosal lesions in rats by tri-potassium di-citrato bismuthate.
    Malandrino S; Campagnoli G; Borsa M; Guidoboni R; Tonon GC
    Arzneimittelforschung; 1984; 34(1):30-1. PubMed ID: 6367754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of colloidal bismuth subcitrate on age related gastric lesions in the rat.
    Hinsull SM
    Gut; 1991 Apr; 32(4):355-60. PubMed ID: 2026333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effects of colloidal bismuth subcitrate and aluminum hydroxide on gastric and duodenal levels of prostaglandin E2].
    Estela R; Feller A; Backhouse C; Castro R; Ugarte G
    Rev Med Chil; 1984 Oct; 112(10):975-81. PubMed ID: 6399150
    [No Abstract]   [Full Text] [Related]  

  • 39. Drug therapy for peptic ulcer: drugs that act on the gastric mucosa.
    Kauffman GL
    J Clin Gastroenterol; 1981; 3(Suppl 2):95-101. PubMed ID: 6119340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological properties of colloidal bismuth subcitrate (CBS, DE-NOL).
    Wieriks J; Hespe W; Jaitly KD; Koekkoek PH; Lavy U
    Scand J Gastroenterol Suppl; 1982; 80():11-6. PubMed ID: 6962539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.